

Supplementary Figure 2: Succesful Pl3Kδ combination therapy is tumour model dependent. (A) Schematic diagram shows the experimental protocol: MC38 mice were treated daily for the duration of the study with either 75mg/kg of Pl-3065 or vehicle by oral gavage and were administered anti-LAG3 (250μg) at the days indicated (8 mice/group). Individual growth curves from MC38 tumour bearing mice treated with (B) vehicle (C) Pl-3065 (D) vehicle + anti-LAG3 or (E) Pl-3065 + anti-LAG3.